STOCK TITAN

Achieve Life Sciences (ACHV) grants director stock awards

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Achieve Life Sciences director Thomas Sellig received equity awards comprising 25,000 stock options with an exercise price of $6.18 per share and 16,700 restricted stock units (RSUs), each RSU representing one share of common stock.

Both the options and RSUs vest 100% on the earlier of July 27, 2027 or the date immediately prior to Achieve Life Sciences’ 2027 annual meeting of stockholders, contingent on his continued service.

Positive

  • None.

Negative

  • None.
Insider Sellig Thomas
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F1 25,000 $0.00 $0.00
Grant/Award Restricted Stock Unit (RSU) F2, F3 16,700 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct); Restricted Stock Unit (RSU) — 16,700 shares (Direct)
Footnotes (3)
  1. F1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
  2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
  3. F3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Stock options granted 25000.0000 shares Options to purchase Achieve Life Sciences common stock granted to director Thomas Sellig
Option exercise price $6.1800 per share Exercise price for stock options granted on July 27, 2026
Option expiration date July 27, 2036 Expiration date of stock options awarded to Thomas Sellig
RSUs granted 16700.0000 units Restricted Stock Units representing Achieve Life Sciences common stock granted to Thomas Sellig
Vesting trigger date July 27, 2027 Earlier of this date or immediately prior to 2027 annual meeting, subject to continued service
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of $6.18 per share"
Restricted Stock Unit (RSU) financial
"Restricted Stock Unit (RSU) represents a contingent right to receive one share"
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
vesting financial
"The options and RSUs vest 100% on the earlier of July 27, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"Exercise price of $6.18 per share applies to the stock options granted"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of stockholders regulatory
"Awards vest on the earlier of July 27, 2027 or immediately prior to the 2027 annual meeting of stockholders"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Achieve Life Sciences (ACHV) grant to director Thomas Sellig?

Thomas Sellig received 25,000 stock options with a $6.18 exercise price and 16,700 RSUs. Each RSU corresponds to one share of common stock, providing a mix of options and full-value share units as part of his director compensation.

What are the vesting terms of the new equity awards for ACHV director Thomas Sellig?

Both the 25,000 options and 16,700 RSUs vest 100% on the earlier of July 27, 2027 or the date immediately before Achieve Life Sciences’ 2027 annual meeting, provided Sellig continues to serve the company through the vesting date.

What is the exercise price and expiration date of the stock options granted by ACHV?

The stock options granted to Thomas Sellig have an exercise price of $6.18 per share and an expiration date of July 27, 2036. He can purchase common stock at this price once the options vest and before they expire.

How many shares of Achieve Life Sciences (ACHV) common stock could these awards deliver?

If fully vested and settled, the awards cover 25,000 shares through stock options and 16,700 shares through RSUs. Each RSU represents a contingent right to receive one share of Achieve Life Sciences common stock upon settlement.

Are the reported ACHV equity grants to Thomas Sellig under a Rule 10b5-1 trading plan?

The equity awards are not indicated as made under a Rule 10b5-1 trading plan. The Rule 10b5-1 checkbox is shown as unchecked, and the footnotes describe vesting terms but do not reference any pre-arranged trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sellig Thomas

(Last)(First)(Middle)
22722 29TH DR SE
SUITE 100

(Street)
BOTHELL WASHINGTON 98021

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$6.1807/27/2026A25,000 (1)07/27/2036Common Stock25,000$025,000D
Restricted Stock Unit (RSU)(2)07/27/2026A16,700 (3)07/27/2036Common Stock16,700$016,700D
Explanation of Responses:
1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
Sandra Thomson as attorney-in-fact07/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)